Cookie Policy

By clicking "Accept", you are agreeing to continue browsing and accept the website privacy policy.

Responsive image

Drug Information

Drug Generic Name ACITRETIN
Drug Class PREPARATION FOR PSORIASIS AND ECZEMA
Chapter Skin

This is a metabolite of etretinate

Indications severe resistant or complicated psoriasis, congenital disorders of keratinization including Darier's disease (keratosis follicularis).

Cautions: avoid in hepatic impairment, monitor liver function and plasma lipids (especially in patients with hypertriglyceridaemia) 1 month after initiating treatment and then at 3 monthly intervals. Exclude pregnancy before starting; patients should avoid pregnancy at least 1 month before, during and for at least 2 years after treatment; should avoid concomitant high doses of vitamin A and should not donate blood during or for 2 years after stopping therapy (teratogenic risk); radiographic assessment on long-term treatment; investigate atypical musculoskeletal symptoms; avoid long term use in children (skeletal hyperostosis and extra- osseous calcification).

Contra-indications: hepatic and renal impairment; pregnancy and breast-feeding.

Side Effects: (Mainly dose-related) dryness and erosion of mucous membranes, scaling, thinning erythema and pruritis of skin and conjunctiva; palmar and plantar exfoliation, epistaxis and epidermal fragility; paronychia, reversible alopecia; myalgia and anthralgia; nausea, headache, malaise, drowsiness and sweating; benign intracranial hypertension; raised liver enzymes, jaundice and hepatitis, raised triglycerides.

Dose: initially 25-30 mg daily for 2-4 weeks. Maintenance, 25-50 mg daily (may reach 75 mg in some cases) for further 6-8 weeks.

Child, (in very exceptional cases only) 500 mcg/kg. daily with careful monitoring of musculoskeletal development.

Brand Name
  • Neotigason 10mg, 25mg Capsules
rating - 1 starrating - 2 starrating - 3 starrating - 4 starrating - 5 star 0 (0 Votes)